Citations

Clear

3485 citation(s) found for "Sy, Sarah".

Abstract 1307: Identification of novel epithelial ovarian cancer loci in women of African ancestry from the Ovarian Cancer Association Consortium
Peres, Lauren C. , Wang, Xin-Qun , Lawrenson, Kate , Abbott, Sarah, Schwartz, Ann G. , Wu, Anna H. , Peters, Edward , Moorman, Patricia G. , Kelemen, Linda E., Goode, Ellen L. , Gather, Simon A., Schildkraut, Joellen, Manichaikul, Ani , Abbott, Sarah, Coté, Michele L. , Bondy, Melissa L. , Barnholtz‐Sloan, Jill S. , Berchuck, Andrew , Doherty, Jennifer A. , Pharoah, Paul D.P. , Lawrenson, Kate

Mayo Clinic

Cancer Research | July 31, 2017 | Volume: 77 | Issue: 13_Supplement | Pages: 1307-1307

10.1158/1538-7445.am2017-1307 Get It

Abstract Epithelial ovarian cancer (EOC) is a rare but deadly disease for which there is notably poorer survival in women of African Ancestry (AA) compared to women of European Ancestry (EA). Previous EA-based genome-wide association studies (GWAS) have identified 30 common, low penetrant EOC susceptibility alleles. Using the custom-designed 533,631 SNP Illumina OncoArray and imputation to ~12 million genetic variants in the 1000 Genomes Phase 3, we conducted a GWAS in 755 AA EOC cases, including 537 high-grade serous ovarian cancer (HGSOC) cases, and 1,235 AA controls from the Ovarian Cancer Association Consortium (OCAC). We identified novel susceptibility loci with suggestive evidence of association with EOC, based on a threshold of P<1x10-6, at three distinct loci including 10p15.1 (lead SNP rs4525119, intronic to AKR1C3, P=4.9 x 10-7, minor allele frequency [MAF]=0.33), 3p25.3 (lead SNP rs7643459, intronic to LOC101927394, P=8.4 x 10-7, MAF=0.36), and 4q13.3 (lead SNP rs4286604, 15 kb 3’ of UGT2A1, P=8.5x10-7, MAF=0.27). In analysis of HGSOC, we identified suggestive evidence of association at six distinct loci including 5q11.2 (lead SNP rs37792, 132 kb 5’ of FST, P=6.0x10-8, MAF=0.34), Xq27.2 (lead SNP rs57403204, 81 kb 3' of MAGEC1, P=1.7x10-7, MAF=0.06), 10p15.1 (lead SNP rs79079890, LOC105376360 intronic, P=3.0x10-7, MAF=0.03), 17p25.1 (lead SNP rs66459581, 5 kb 5’ of PRPSAP1, P=5.1x10-7, MAF=0.23), 15p12 (lead SNP rs116046250, GABRG3 intronic, P=8.7x10-7, MAF=0.05), and 4q21.21 (lead SNP rs192876988, 30 kb 3’ of GK2, P=9.2x10-7, MAF=0.05). These SNPs showed no evidence of association with risk in the OCAC EA GWAS including up to 23,543 EOC cases and 29,444 controls. Of the SNPs identified with suggestive evidence of association in our GWAS, two are located near genes known to regulate hormones and previously reported in relation to diseases of the ovary (AKR1C3 and FST), two have been linked to cancer (AKR1C3 and MAGEC1) and one represents testis-specific expression (GK2). Of the 30 SNPs identified previously in a EA EOC GWAS, we observed nominally significant associations (P<0.05) with consistent direction of effect for eight SNPs in AA women. Our investigation presents evidence of (1) variants for EOC shared among EA and AA women and (2) novel EOC risk loci of importance for AA women. Citation Format: Ani Manichaikul, Lauren C. Peres, Xin-Qun Wang, Kate Lawrenson, Sarah Abbott, Ann G. Schwartz, Anna H. Wu, Edward Peters, Patricia G. Moorman, Michele L. Cote, Melissa Bondy, Linda Kelemen, Ellen L. Goode, Jill Barnholtz-Sloan, Simon A. Gather, Andrew Berchuck, Jennifer A. Doherty, Paul Pharoah, Joellen Schildkraut. Identification of novel epithelial ovarian cancer loci in women of African ancestry from the Ovarian Cancer Association Consortium [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 1307. doi:10.1158/1538-7445.AM2017-1307
Abstract 1302: Genome-wide association study of glioma reveals specific differences in genetic susceptibility to glioblastoma and non-glioblastoma
Kinnersley, Ben , Melin, Beatrice , Wrensch, Margaret , Johansen, Christoffer , Ostrom, Quinn T. , GICC, and members of, Labrèche, Karim , Eckel‐Passow, Jeanette E. , Decker, Paul A. , Labussière, Marianne, Delattre, Jean‐Yves, Gousias, Konstantinos , Schramm, Johannes, Schoemaker, Minouk J. , Nöthen, Marcus M., Wichmann, Heinz‐Erich, Lathrop, Mark, Simon, Matthias , Chanock, Stephen, Linet, Martha S. , Lai, Rose , Claus, Elizabeth B. , Jenkins, Robert B. , Houlston, Richard S. , Barnholtz‐Sloan, Jill S. , Il’yasova, Dora , GICC, and members of, Decker, Paul A. , Idbaïh, Ahmed , Hoang‐Xuan, Khê , Stefano, Anna Luisa Di , Mokhtari, Karima , Galán, Pilar , Fleming, Sarah , Herms, Stefan , Heilmann‐Heimbach, Stefanie , Schreiber, Stefan , Swerdlow, Anthony J. , Sanson, Marc , Rajaraman, Preetha , Wang, Zhaoming , Yeager, Meredith , Olson, Sara H. , Bondy, Melissa L. , Houlston, Richard S , Schoemaker, Minouk J , Ostrom, Quinn T

Mayo Clinic

Cancer Research | July 31, 2017 | Volume: 77 | Issue: 13_Supplement | Pages: 1302-1302

10.1158/1538-7445.am2017-1302 Get It

Abstract BACKGROUND: Glioma accounts for ~27% of all primary brain tumors and is responsible for ~13,000 cancer-related deaths in the US each year. Glioma tumors can be broadly classified into glioblastoma (GBM) and lower-grade non-GBM. Typically gliomas have a poor prognosis irrespective of medical care, with the most common form, GBM, having a five-year survival rate of only 5%. While genome-wide association studies (GWAS) have transformed our understanding of glioma susceptibility, individual studies have had limited power to identify risk loci. METHODS: We performed the largest glioma GWAS to date, comprising a meta-analysis of six existing GWAS (6,405 cases, 14,100 controls) as well as new GWAS from the Glioma International Case Control Consortium (GICC; 4,572 cases and 3,286 controls) and University of California, San Francisco (UCSF)-Mayo (1,519 cases, 804 controls), totaling 12,496 cases (6,191 classified as GBM, 5,819 as non-GBM) and 18,190 controls. RESULTS: We identified five new risk loci for GBM at 1p31.3 (rs12752552; near JAK1, P=2.04×10-9, odds ratio (OR)=1.22), 11q14.1 (rs11233250; P=9.95×10-10, OR=1.24), 16p13.3 (rs2562152; near MPG, P=1.93x10-8, OR=1.21), 16q12.1 (rs10852606; HEATR3, P=1.29×10-11, OR=1.18), 22q13.1 (rs2235573; P=1.76×10-10, OR=1.15) and eight for non-GBM at 1q32.1 (rs4252707; MDM4, P=3.34×10-9, OR=1.19), 1q44 (rs12076373; AKT3, P=2.63×10-10, OR=1.23), 2q33.3 (rs7572263; near IDH1, P=2.18×10-10, OR=1.20), 3p14.1 (rs11706832; LRIG1, P=7.66×10-9, OR=1.15), 10q24.33 (rs11598018; OBFC1, P=3.39×10-8, OR=1.14), 11q21 (rs7107785; P=3.87×10-10, OR=1.16), 14q12 (rs10131032; P=5.07x10-11, OR=1.33) and 16p13.3 (rs3751667; P=2.61×10-9, OR=1.18). Case-only analyses confirmed the specificity of 11q14.1, 16p13.3 and 22q13.1 associations for GBM and 1q44, 2q33.3, 3p14.1, 11q21 and 14q12 for non-GBM tumors. In the combined meta-analysis, among previously published glioma risk SNPs, those for all glioma at 17p13.1 (TP53), GBM at 5p15.33 (TERT), 7p11.2 (EGFR), 9p21.3 (CDKN2B-AS1) and 20q13.33 (RTEL1) and for non-GBM at 8q24.21 (CCDC26), 11q23.2, 11q23.3 (PHLDB1) and 15q24.2 (ETFA) showed even greater evidence for association. SNPs at 10q25.2 and 12q12.1 for non-GBM tumors retained genome-wide significance (i.e. P<5.0x10-8). Associations at the previously reported loci for GBM at 3q26.2 (near TERC) and 12q23.33 (POLR3B) did not retain statistical significance. CONCLUSIONS: Our findings substantiate genetic susceptibility to GBM and non-GBM glioma being highly distinct, consistent with their distinctive molecular profiles presumably resulting from different etiological pathways. Functional analyses should lead to further insights into the biological basis of the different glioma histologies. Such information can inform gene discovery initiatives and therefore have a measurable impact on the successful development of new therapeutic agents. Citation Format: Ben Kinnersley, Beatrice S. Melin, Jill S. Barnholtz-Sloan, Margaret R. Wrensch, Christoffer Johansen, Dora Il’yasova, Quinn Ostrom, and members of GICC, Karim Labreche, Jeanette E. Eckel-Passow, Paul A. Decker, Marianne Labussière, Ahmed Idbaih, Khe Hoang-Xuan, Anna-Luisa Di Stefano, Karima Mokhtari, Jean-Yves Delattre, Pilar Galan, Konstantinos Gousias, Johannes Schramm, Minouk J. Schoemaker, Sarah J. Fleming, Stefan Herms, Stefanie Heilmann, Marcus M. Nöthen, Heinz-Erich Wichmann, Stefan Schreiber, Anthony Swerdlow, Mark Lathrop, Matthias Simon, Marc Sanson, Preetha Rajaraman, Stephen Chanock, Martha Linet, Zhaoming Wang, Meredith Yeager, Rose K. Lai, Elizabeth B. Claus, Sara H. Olson, Robert B. Jenkins, Richard S. Houlston, Melissa L. Bondy. Genome-wide association study of glioma reveals specific differences in genetic susceptibility to glioblastoma and non-glioblastoma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 1302. doi:10.1158/1538-7445.AM2017-1302
Pediatric Phase I Trial and Pharmacokinetic Study of Trebananib in Relapsed Solid Tumors, Including Primary Tumors of the Central Nervous System ADVL1115: A Children's Oncology Group Phase I Consortium Report
Ralya, Andrew T., Baruchel, Sylvain , Wu, Bing , Liu, Xiaowei , Fox, Elizabeth , Weigel, Brenda J. , Blaney, Susan M. , Reid, Joel M. , Leary, Sarah , Park, Julie R. , Roberts, Timothy P. L. , Minard, Charles G.

Mayo Clinic

Clinical Cancer Research | July 28, 2017 | Volume: 23 | Issue: 20 | Pages: 6062-6069

10.1158/1078-0432.ccr-16-2882 | PMID 28751444 Get It

Abstract Purpose: Trebananib is a first-in-class antiangiogenic peptibody (peptide–Fc fusion protein) that inhibits Angiopoietin 1 and 2. A pediatric phase 1 trial was performed to define trebananib dose-limiting toxicities (DLT), recommended phase 2 dose (RP2D), and pharmacokinetics (PK). Experimental Design: Trebananib was administered by weekly infusion. Three dose levels (10, 15, or 30 mg/kg/dose) were evaluated using a rolling-six design. Part 2 evaluated a cohort of subjects with primary central nervous system (CNS) tumors. Pharmacokinetic sampling and analysis of peripheral blood biomarkers was performed during the first 4 weeks. Response was evaluated after 8 weeks. Correlative studies included angiogenic protein expression and DCE-MRI. Results: Thirty-seven subjects were enrolled (31 evaluable for toxicity) with median age 12 years (range, 2 to 21). Two of 19 evaluable non-CNS subjects developed DLT at the 30 mg/kg dose level, including venous thrombosis and pleural effusion. In the CNS cohort, 3/12 subjects developed DLT, including decreased platelet count, transient ischemic attack, and cerebral edema with headache and hydrocephalus. Other grade 3 or 4 toxicities included lymphopenia (n = 4), anemia, thrombocytopenia, neutropenia, vomiting, and hypertension (n = 1 each). Response included stable disease in 7 subjects, no partial or complete responses. Two subjects continued study treatment with prolonged stable disease for 18 cycles (neuroblastoma) and 26 cycles (anaplastic astrocytoma). Pharmacokinetics appeared linear over 3 dose levels. Correlative studies demonstrated increased PlGF and sVCAM-1, but no change in endoglin or perfusion by DCE-MRI. Conclusions: Trebananib was well tolerated in pediatric patients with recurrent or refractory solid or CNS tumors. RP2D is 30 mg/kg. Clin Cancer Res; 23(20); 6062–9. ©2017 AACR.
Investigation of factors affecting the efficacy of 3C23K, a human monoclonal antibody targeting MISIIR
Gill, Sarah , Zhang, Qing , Keeney, Gary L., Cliby, William A. , Weroha, S. John , Gill, Sarah E

Mayo Clinic

Oncotarget | July 27, 2017 | Volume: 8 | Issue: 49 | Pages: 85214-85223

10.18632/oncotarget.19620 | PMID 29156714 Get It

Ultrasound guided percutaneous common carotid artery access in piglets for intracoronary stem cell infusion
Taggart, Nathaniel W. , Edgerton, Sarah, Peral, Susana Cantero, Holst, Kimberly , Cetta, Frank , Anderson, Jason H. , Edgerton, Sarah L, Cantero Peral, Susana, Holst, Kimberly A, Taggart, Nathaniel W

Mayo Clinic

Laboratory Animals | July 20, 2017 | Volume: 52 | Issue: 1 | Pages: 88-92

10.1177/0023677217719923 | PMID 28708034 Get It

In pigs, the deep location of the common carotid artery and overlying sternomastoideus muscle in the neck has led to the recommendation for a surgical cutdown for common carotid access, as opposed to minimally invasive techniques for vascular access. We sought to determine if direct percutaneous common carotid artery access in piglets is attainable. Seventeen piglets were anesthetized and intubated. Under two-dimensional and color flow Doppler ultrasound guidance, a 21 gauge needle was utilized to access the right common carotid artery. Following arterial puncture, the Seldinger technique was applied to place a 4 or 5 French introducer. Upon completion of cardiac catheterization with intracoronary stem cell infusion the introducer was removed and manual pressure was applied to prevent hematoma development. Successful access with an introducer was achieved in all 17 piglets. The average weight was 8.5 ± 1.7 kg. One piglet developed a hematoma with hemorrhaging from the catheterization site and was euthanized. This piglet was given bivalirudin for the procedure. After this incident, subsequent piglets were not given anticoagulation and no other complications occurred. Ultrasound guided percutaneous common carotid artery access in piglets is attainable in a safe, reliable, and reproducible manner when performed by microvascular experts.
Long-term rates of mitochondrial protein synthesis are increased in mouse skeletal muscle with high-fat feeding regardless of insulin-sensitizing treatment
Newsom, Sean A. , Miller, Benjamin F. , Hamilton, Karyn L. , Ehrlicher, Sarah E., Stierwalt, Harrison D. , Robinson, Matthew M.

Mayo Clinic

American Journal of Physiology-Endocrinology and Metabolism | July 11, 2017 | Volume: 313 | Issue: 5 | Pages: E552-E562

10.1152/ajpendo.00144.2017 | PMID 28698283 Get It

Skeletal muscle mitochondrial protein synthesis is regulated in part by insulin. The development of insulin resistance with diet-induced obesity may therefore contribute to impairments to protein synthesis and decreased mitochondrial respiration. Yet the impact of diet-induced obesity and insulin resistance on mitochondrial energetics is controversial, with reports varying from decreases to increases in mitochondrial respiration. We investigated the impact of changes in insulin sensitivity on long-term rates of mitochondrial protein synthesis as a mechanism for changes to mitochondrial respiration in skeletal muscle. Insulin resistance was induced in C57BL/6J mice using 4 wk of a high-fat compared with a low-fat diet. For 8 additional weeks, diets were enriched with pioglitazone to restore insulin sensitivity compared with nonenriched control low-fat or high-fat diets. Skeletal muscle mitochondrial protein synthesis was measured using deuterium oxide labeling during weeks 10–12. High-resolution respirometry was performed using palmitoyl-l-carnitine, glutamate+malate, and glutamate+malate+succinate as substrates for mitochondria isolated from quadriceps. Mitochondrial protein synthesis and palmitoyl- l-carnitine oxidation were increased in mice consuming a high-fat diet, regardless of differences in insulin sensitivity with pioglitazone treatment. There was no effect of diet or pioglitazone treatment on ADP-stimulated respiration or H2O2 emission using glutamate+malate or glutamate+malate+succinate. The results demonstrate no impairments to mitochondrial protein synthesis or respiration following induction of insulin resistance. Instead, mitochondrial protein synthesis was increased with a high-fat diet and may contribute to remodeling of the mitochondria to increase lipid oxidation capacity. Mitochondrial adaptations with a high-fat diet appear driven by nutrient availability, not intrinsic defects that contribute to insulin resistance.
Illness Understanding of Oncology Patients in a Community-Based Cancer Institute
Sivendran, Shanthi , Jenkins, Sarah M. , Svetec, Sarah, Horst, Michael, Newport, Kristina , Yost, Kathleen J. , Yang, Manshu

Mayo Clinic

Journal of Oncology Practice | July 5, 2017 | Volume: 13 | Issue: 9 | Pages: e800-e808

10.1200/jop.2017.020982 | PMID 28678589 Get It

Purpose: Several studies have demonstrated that patients have a poor understanding of prognosis, survival, and effectiveness of chemotherapy, particularly in the setting of advanced cancer. This study examines oncology patients’ understanding of their illness based on accurate reporting of stage at diagnosis and knowledge of cancer status (ie, free of cancer or in remission v active disease). Materials and Methods: Two hundred eight patients with cancer previously treated at our large community-based cancer institute participated in the Consumer-Based Cancer Care Value Index field survey. Electronic medical record documentation of stage at diagnosis and cancer status was compared with patients’ self-reported responses. Concordance of responses and variables influencing discordance were evaluated. Results: In 51.0% of patients, self-reported cancer stage matched the abstracted stage, with the highest concordance in patients with advanced cancer (72%) versus patients with stage I to III disease (36.4% to 61.5%). Unexpectedly, discordance was lower among patients with advanced cancer compared with patients with stage I to III cancer ( P = .0528). Patients who were concordant for cancer stage at diagnosis were significantly more likely to be female ( P = .001), be younger than age 65 years ( P = .01), have an income > $60,000 ( P = .03), and have more education ( P = .02). In 64.4% of patients, self-reported cancer status (ie, free of cancer or in remission v active disease) matched the abstracted status. Nearly 30% of patients were not sure about their status, even when they were free of cancer or in remission. Conclusion: Our findings confirm that more than one quarter of patients with advanced cancer have poor illness understanding and highlight that an even greater number of patients with early stage I to III cancer have poor illness understanding. These observations highlight the need to improve illness understanding for patients across the entire cancer continuum.
Assessment of pancreatic neuroendocrine tumor cytologic genotype diversity to guide personalized medicine using a custom gastroenteropancreatic next-generation sequencing panel
Gleeson, Ferga C. , Voss, Jesse S. , Kipp, Benjamin R. , Kerr, Sarah E. , Arnam, John S. Van , Mills, John R. , Marcou, Cherisse A. , Schneider, Amber, Tu, Zheng Jin, Henry, Michael , Levy, Michael J. , Van Arnam, John S, Schneider, Amber R, Henry, Michael R, Levy, Michael J.

Mayo Clinic

Oncotarget | June 28, 2017 | Volume: 8 | Issue: 55 | Pages: 93464-93475

10.18632/oncotarget.18750 | PMID 29212165 Get It

Multisystem Imaging Findings of Cystic Fibrosis in Adults: Recognizing Typical and Atypical Patterns of Disease
Averill, Sarah , Lubner, Meghan G. , Menias, Christine O. , Mellnick, Vincent M. , Kennedy, Tabassum A. , Pickhardt, Perry J. , Bhalla, Sanjeev , Mellnick, Vincent

Mayo Clinic

American Journal of Roentgenology | June 22, 2017 | Volume: 209 | Issue: 1 | Pages: 3-18

10.2214/ajr.16.17462 | PMID 28639921 Get It

Healthcare Provider Education to Support Integration of Pharmacogenomics in Practice: The Emerge Network Experience
Vitek, Carolyn R. Rohrer , Abul‐Husn, Noura S. , Connolly, John J. , Hartzler, Andrea L. , Kitchner, Terrie, Peterson, Josh F. , Rasmussen, Luke V. , Smith, Maureen E. , Stallings, Sarah , Wolf, Wendy A. , Prows, Cynthia A. , Rohrer Vitek, Carolyn R, Williams, Marc S , Rasmussen, Luke V , Connolly, John J , Peterson, Josh F

Mayo Clinic

Pharmacogenomics | June 22, 2017 | Volume: 18 | Issue: 10 | Pages: 1013-1025

10.2217/pgs-2017-0038 | PMID 28639489 Get It